Pooled Analysis of Pralatrexate Single-Agent Studies in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
In conclusion, these pooled analysis results further support using pralatrexate in patients with r/r PTCL. Prospective studies are needed to confirm the findings of subgroups analyses.PMID:38429077 | DOI:10.1182/bloodadvances.2023010441 (Source: Adv Data)
Source: Adv Data - March 1, 2024 Category: Epidemiology Authors: Owen A O'Connor Bor-Sheng Ko Ming-Chung Wang Dai Maruyama Yuqin Song Ee Min Yeoh Nick Manamley Kensei Tobinai Source Type: research
Experience with bexarotene to treat cutaneous T-cell lymphomas: a study of the Spanish Working Group of Cutaneous Lymphomas
CONCLUSIONS: Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.PMID:38395224 | DOI:10.1016/j.ad.2023.12.007 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - February 23, 2024 Category: Dermatology Authors: R Izu-Belloso I Gainza-Apraiz P Ortiz-Romero O Servitje-Bedate R Fern ández de Misa-Cabrera Y Pe ñate-Santana B Hernandez-Machin T Estrach-Panella M Llamas-Velasco J I Yanguas-Bayona M Morillo-Andujar E Acebo-Mari ñas S Perez-Gala J C Armario-Hita P Sa Source Type: research
Cancers, Vol. 16, Pages 861: JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression. (Source: Cancers)
Source: Cancers - February 21, 2024 Category: Cancer & Oncology Authors: Seyed Mohammad Vahabi Saeed Bahramian Farzad Esmaeili Bardia Danaei Yasamin Kalantari Patrick Fazeli Sara Sadeghi Nima Hajizadeh Chalid Assaf Ifa Etesami Tags: Systematic Review Source Type: research
Systemic inflammation and its relationship with pruritus in early-stage mycosis fungoides
This study provides evidence of enhanced systemic inflammation in early-stage MF patients. Additionally, the correlation between pruritus with mSWAT scores and systemic inflammation parameters suggests a potential link between pruritus and the inflammatory milieu in MF.PMID:38332520 | PMC:PMC10853580 | DOI:10.1111/jcmm.18125 (Source: J Cell Mol Med)
Source: J Cell Mol Med - February 9, 2024 Category: Molecular Biology Authors: Berna Solak Rabia Öztaş Kara Source Type: research
GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells
Oncotarget. 2024 Feb 8;15:124-133. doi: 10.18632/oncotarget.28557.ABSTRACTGZ17-6.02, composed of curcumin, harmine and isovanillin, has undergone phase I evaluation in patients with solid tumors (NCT03775525) with an RP2D of 375 mg PO BID. The biology of GZ17-6.02 in malignant T cells and in particular those derived from mycosis fungoides (MF) patients, has not been studied. GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells. All three components are necessary for optimal killing of MF cells. GZ17-6.02 activated ATM, the AMPK, NFκB and PERK and inactivated ERK1/2, AKT, ULK1, ...
Source: Oncotarget - February 8, 2024 Category: Cancer & Oncology Authors: Michael R Booth Laurence Booth Jane L Roberts Cameron West Paul Dent Source Type: research
